myo-Inositol trispyrophosphate

Technopedia Center

Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education

myo-Inositol trispyrophosphate - Wikipedia

From Wikipedia, the free encyclopedia

*myo*-Inositol trispyrophosphate
Names

Other names ITPP myo-Inositol cyclic 1,2:3,4:5,6-tris(dihydrogen pyrophosphate) myo-Inositol cyclic 1,2:3,4:5,6-tris(P,P'-dihydrogen diphosphate) Hexahydrobis[1,3,5,2,4]trioxadiphosphepino[6,7-g:6',7'-i][1,3,5,2,4]benzotrioxadiphosphepine-2,4,7,9,12,14-hexol 2,4,7,9,12,14-hexaoxide
Identifiers
CAS Number	623552-11-4
3D model (JSmol)	Interactive image
ChemSpider	8615402
MeSH	C516441
PubChem CID	10439981
InChI InChI=1S/C6H12O21P6/c7-28(8)19-1-2(20-29(9,10)25-28)4-6(24-33(17,18)27-32(15,16)23-4)5-3(1)21-30(11,12)26-31(13,14)22-5/h1-6H,(H,7,8)(H,9,10)(H,11,12)(H,13,14)(H,15,16)(H,17,18) Key: HEDKSUBRULAYNO-UHFFFAOYSA-N InChI=1S/C6H12O21P6/c7-28(8)19-1-2(20-29(9,10)25-28)4-6(24-33(17,18)27-32(15,16)23-4)5-3(1)21-30(11,12)26-31(13,14)22-5/h1-6H,(H,7,8)(H,9,10)(H,11,12)(H,13,14)(H,15,16)(H,17,18) Key: HEDKSUBRULAYNO-UHFFFAOYSA-N
SMILES C12C(C3C(C4C1OP(=O)(OP(=O)(O4)O)O)OP(=O)(OP(=O)(O3)O)O)OP(=O)(OP(=O)(O2)O)O
Properties
Chemical formula	C₆H₁₂O₂₁P₆
Molar mass	605.984 g·mol⁻¹
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

myo-Inositol trispyrophosphate (ITPP) is an inositol phosphate, a pyrophosphate, a drug candidate, and a putative performance-enhancing substance, which exerts its biological effects by increasing tissue oxygenation.^[1]

Chemistry

ITPP is a pyrophosphate derivative of phytic acid with the molecular formula C₆H₁₂O₂₁P₆.^[1]

Biological effects

ITPP is a membrane-permeant allosteric regulator of hemoglobin that mildly reduces its oxygen-binding affinity, which shifts the oxygen-hemoglobin dissociation curve to the right and thereby increases oxygen release from the blood into tissue.^[1] Phytic acid, in contrast, is not membrane-permeant due to its charge distribution.^[1]

Rodent studies in vivo demonstrated increased tissue oxygenation and dose-dependent increases in endurance during physical exercise, in both healthy mice and transgenic mice expressing a heart failure phenotype.^[1]

The substance is believed to have a high potential for use in athletic doping, and liquid chromatography–mass spectrometry tests have been developed to detect ITPP in urine tests.^[2] Its use as a performance-enhancing substance in horse racing has also been suspected and similar tests have been developed for horses^[3]

ITPP has been studied for potential adjuvant use in the treatment of cancer in conjunction with chemotherapy, due to its effects in reducing tissue hypoxia.^[4] Human clinical trials were registered in 2014 under the compound number OXY111A.^[5] The substance has also been examined in the context of other illnesses involving hypoxia, such as cardiovascular disease and dementia^[2]

References

^ ^a ^b ^c ^d ^e Biolo, A; Greferath, R; Siwik, DA; Qin, F; Valsky, E; Fylaktakidou, KC; Pothukanuri, S; Duarte, CD; Schwarz, RP; Lehn, JM; Nicolau, C; Colucci, WS (2009). "Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate". Proc Natl Acad Sci U S A. 106 (6): 1926–1929. Bibcode:2009PNAS..106.1926B. doi:10.1073/pnas.0812381106. PMC 2644140. PMID 19204295.
^ ^a ^b Görgens, C; Guddat, S; Schänzer, W; Thevis, M (2014). "Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposes". Drug Test. Anal. 6 (11–12): 1102–1107. doi:10.1002/dta.1700. PMID 25070041.
^ Lam, G; Zhao, S; Sandhu, J; Yi, R; Loganathan, D; Morrissey, B (2014). "Detection of myo-inositol tris pyrophosphate (ITPP) in equine following an administration of ITPP". Drug Test. Anal. 6 (3): 268–276. doi:10.1002/dta.1473. PMID 23733541.
^ Limani, P; Linecker, M; Schneider, MA; Kron, P; Tschuor, C; Kachaylo, E; Ungethuem, U; Nicolau, C; Lehn, JM; Graf, R; Humar, B; Clavien, PA (2017). "The Allosteric Hemoglobin Effector ITPP Inhibits Metastatic Colon Cancer in Mice" (PDF). Ann. Surg. 266 (5): 746–753. doi:10.1097/SLA.0000000000002431. PMID 28742687. S2CID 20565432.
^ Limani, P; Linecker, M; Kron, P (2016). "Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial". BMC Cancer. 16 (1): 812. doi:10.1186/s12885-016-2855-3. PMC 5070093. PMID 27756258.

Categories:

Hidden categories:

Chemistry

Biological effects

See also

References